Rebecca Rodal’s practice concentrates on the intellectual property and technology aspects of mergers and acquisitions, spin-offs and divestitures, financing transactions and other corporate transactions. Ms. Rodal focuses on structuring, drafting and negotiating IP provisions and agreements across a broad range of practice areas. She regularly handles a variety of complex licensing, services, restructuring and other IP transaction matters, and advises on IP strategy, privacy and cybersecurity. She has assisted on the IP aspects of transactions in which patents and knowledge strategy are core deal assets, and has successfully negotiated both short-term and long-term arrangements with respect to use and protection of IP in complex hive-off and carve-out transactions. Ms. Rodal holds a degree in cellular and molecular biology and has particular experience in pharma, biotech and other complex life sciences, chemicals industries and related transactions.

In the context of M&A and other corporate transaction, her representative matters include:

  • Goldman, Sachs & Co. as initial purchaser, structuring agent and bookrunner in Drug Royalty III L.P. 1’s $145 million Rule 144A offering of 3.979% senior secured notes;
  • Deutsche Bank AG in its sale of Deutsche Bank S.A. to Banco Comafi S.A. and in the sale of its banking and broker-dealer businesses in Mexico to Investa Bank, S.A., Institución de Banca Múltiple;
  • Didi Chuxing (Hangzhou Kuaizhi Technology Co., Ltd.) in its acquisition of UberChina from Uber Technologies Inc.;
  • LANXESS AG in its $2.5 billion acquisition of Chemtura Corporation;
  • Merck KGaA in its $17 billion acquisition of Sigma-Aldrich Corporation;
  • Citigroup in its $685 million sale of its global bond analytics business to the London Stock Exchange;
  • SciClone Pharma in its acquisition by a Chinese consortium for $605 million;
  • Intralinks Holdings, Inc. in its $821 million acquisition by Synchronoss Technologies, Inc.;
  • Grupo Ferrer Internacional, S.A. in its acquisition of Alexza Pharmaceuticals Inc.;
  • State Farm Mutual Automobile Insurance Company in connection with the $1.5 billion sale of its Canadian property, casualty and life insurance businesses to Desjardins Group;
  • a syndicate of 18 international banks and other financial institutions in connection with Sasol Limited’s $4 billion credit facility for its ethane cracker at its existing site in Lake Charles, Louisiana;
  • SHFL Entertainment, Inc. in its $1.3 billion acquisition by Bally Technologies, Inc.;
  • E. I. du Pont de Nemours and Company in its $4.9 billion sale of DuPont Performance Coatings to The Carlyle Group;
  • Visteon Corporation in its $265 million acquisition of the automotive electronics business of Johnson Controls Inc.;
  • Joh. A. Benckiser in its $974 million acquisition of Peet’s Coffee & Tea;
  • The Sage Group plc in the $101 million sale of three of its non-core products in the United States to Accel-KKR LLC and SwiftPage; and
  • The Walt Disney Company in its $4 billion acquisition of Lucasfilm Ltd.



  • J.D., University of Toronto, 2010
  • B.Sc., McGill University, 2007


  • Ontario
  • New York

Rebecca Rodal

Associate, Intellectual Property and Technology; Cybersecurity and Privacy